



ISEC HEALTHCARE LTD.
(Company Registration No: 201400185H)
(Incorporated in Singapore)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the Annual General Meeting of **ISEC HEALTHCARE LTD.** will be held at Arthur Lim Auditorium, Level 2, Alumni Medical Centre, 2 College Road, Singapore 169850 on Wednesday, 24 April 2019 at 10.30 a.m. to transact the following business:-

ORDINARY BUSINESS

- To receive and adopt the Directors' Statement and the Audited Financial Statements for the financial year ended 31 December 2018 together with the Independent Auditor's Report thereon. **(Resolution 1)**
- To declare a final tax exempt (one-tier) dividend of 0.78 Singapore cents (S\$0.0078) per ordinary share for the financial year ended 31 December 2018 (FY2017: S\$0.007 per ordinary share). **(Resolution 2)**
- To declare a special tax exempt (one-tier) dividend of 0.98 Singapore cents (S\$0.0098) per ordinary share for the financial year ended 31 December 2018. **(Resolution 3)**
- To re-elect the following Directors of the Company retiring pursuant to Article 114 of the Constitution of the Company, and who have, being eligible, offered themselves for re-election as Directors:
Dr Lee Hung Ming **(Resolution 4)**
Mr Lim Wee Hann **(Resolution 5)**
The profiles of the above mentioned directors can be found under the sections entitled "Board of Directors" and the "Report on Corporate Governance" in the Annual Report 2018.
[See Explanatory Note (i)]
- To approve the payment of Directors' fees of S\$170,000 for the financial year ending 31 December 2019, payable quarterly in arrears. (FY2018: S\$170,000) **(Resolution 6)**
[See Explanatory Note (ii)]
- To re-appoint Ernst & Young LLP as the Independent Auditors of the Company and to authorise the Directors of the Company to fix their remuneration. **(Resolution 7)**
- To transact any other ordinary business which may properly be transacted at an Annual General Meeting.

AS SPECIAL BUSINESS

To consider and if thought fit, to pass the following resolutions as Ordinary Resolutions, with or without any modifications:

8. Authority to allot and issue shares

That pursuant to Section 161 of the Companies Act, Cap. 50 of Singapore (the "Act") and Rule 806 of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist (the "Catalist Rules"), the Directors of the Company be authorised and empowered to:

- allot and issue shares in the capital of the Company ("Shares") whether by way of rights, bonus or otherwise; and/or
- make or grant offers, agreements or options (collectively, "Instruments") that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into Shares,

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors of the Company may in their absolute discretion deem fit; and

- (notwithstanding the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instruments made or granted by the Directors of the Company while this Resolution was in force,

provided that:

- the aggregate number of Shares (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) to be issued pursuant to this Resolution shall not exceed one hundred per centum (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of Shares (including Shares to be issued in pursuance of the Instruments made or granted pursuant to this Resolution) to be issued other than on a pro rata basis to shareholders of the Company shall not exceed fifty per centum (50%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below);
- (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time of the passing of this Resolution, after adjusting for:
 - new Shares arising from the conversion or exercise of any convertible securities;
 - new Shares arising from the exercising of share options or vesting of share awards which are outstanding or subsisting at the time of the passing of this Resolution, provided the share options or share awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and
 - any subsequent bonus issue, consolidation or subdivision of shares;
- in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), the Act and the Constitution, for the time being, of the Company; and
- unless revoked or varied by the Company in a general meeting, such authority shall continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.

[See Explanatory Note (iii)]

(Resolution 8)

9. Authority to issue Shares under the ISEC Healthcare Share Option Scheme (the "Share Option Scheme")

That pursuant to Section 161 of the Singapore Companies Act, Cap. 50, of Singapore, the Directors of the Company be authorised to offer and grant options in accordance with the provisions of the Share Option Scheme and to allot and issue from time to time such number of Shares in the capital of the Company as may be required to be allotted and issued pursuant to the exercise of options under the Share Option Scheme, provided always that the aggregate number of new Shares to be allotted and issued pursuant to the Share Option Scheme, when added to the aggregate number of Shares issued and issuable in respect of all options granted under the Share Option Scheme and any other share option, share incentive, performance share or restricted share plan implemented by the Company, shall not exceed 15% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company on the day preceding the date of grant of the option, as determined in accordance with the provisions of the Share Option Scheme.

[See Explanatory Note (iv)]

(Resolution 9)

10. Authority to issue Shares under the ISEC Healthcare Performance Share Plan (the "Performance Share Plan")

That pursuant to Section 161 of the Singapore Companies Act, Cap. 50, of Singapore, the Directors of the Company be authorised and empowered to grant awards in accordance with the provisions of the Performance Share Plan and to allot and issue from time to time, such number of Shares in the capital of the Company as may be required to be allotted and issued pursuant to the vesting of awards under the Performance Share Plan, provided always that the aggregate number of Shares issued and issuable in respect of all awards granted under the Performance Share Plan, when added to all Shares issued and issuable in respect of the ISEC Healthcare Share Option Scheme and any other share scheme implemented by the Company for the time being in force, shall not exceed fifteen per centum (15%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) of the Company on the day preceding the date of grant of the award.

[See Explanatory Note (v)]

(Resolution 10)

11. Proposed Renewal of the Share Buyback Mandate

THAT

- for the purposes of Sections 76C and 76E of the Singapore Companies Act, Cap. 50, of Singapore (the "Act"), the Directors of the Company be and are hereby authorised to exercise all the powers of the Company to purchase or otherwise acquire Shares not exceeding in aggregate the Prescribed Limit (as hereinafter defined), at such price(s) as may be determined by the Directors of the Company from time to time up to the Maximum Price (as hereinafter defined), whether by way of:
 - market purchases transacted on Catalist through the ready market, and which may be transacted through one or more duly licensed stockbrokers appointed by the Company for the purpose of the share buyback ("Market Purchases"); and/or
 - off-market purchases effected pursuant to an equal access scheme as defined in Section 76C of the Act ("Off-Market Purchase"), and otherwise in accordance with all other laws and regulations, including but not limited to, the Company's Constitution, the provisions of the Act and the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist ("Catalist Rules") as may for the time being be applicable (the "Share Buyback Mandate");
- any Share that is purchased or otherwise acquired by the Company pursuant to the Share Buyback Mandate shall, at the discretion of the Directors of the Company, either be cancelled or held in treasury and dealt with in accordance with the Act;
- unless varied or revoked by the Company in general meeting, the authority conferred on the Directors of the Company pursuant to the Share Buyback Mandate may be exercised by the Directors at any time and from time to time during the period commencing from the passing of this Resolution and expiring on the earlier of:
 - the date on which the next AGM of the Company is held or is required by law to be held;
 - the date on which the purchases or acquisitions of the shares pursuant to the Share Buyback Mandate is carried out to the full extent mandated; or
 - the date on which the authority conferred in the Share Buyback Mandate is varied or revoked by the shareholders in a general meeting, whichever is the earliest ("Relevant Period").
- for purposes of this Resolution:
"Prescribed Limit" means 10% of the total number of issued ordinary shares of the Company ("Shares") as at the date of passing of this Resolution unless the Company has, at any time during the Relevant Period, effected a reduction of the share capital of the Company in accordance with the applicable provisions of the Act, in which event the total number of Shares shall be taken to be the total number of Shares as altered (excluding any treasury shares and subsidiary holdings that may be held by the Company from time to time); and
"Maximum Price" in relation to a Share to be purchased, means the purchase price (excluding brokerage, stamp duties, commission, applicable goods and services tax and other related expenses) not exceeding:
 - in the case of a Market Purchase, 105% of the Average Closing Price; and
 - in the case of an Off-Market Purchase pursuant to an equal access scheme, 120% of the Average Closing Price,where:
 - "Average Closing Price" means the average of the closing market prices of a Share over the last five market days, on which transactions in the Shares were recorded, before the day on which the purchase or acquisition of Shares was made, or as the case may be, the day of the making of the offer pursuant to the Off-Market Purchase, and deemed to be adjusted for any corporate action that occurs after the relevant five (5)-day period;

(iv) "day of the making of the offer" means the day on which the Company announces its intention to make an offer for an Off-Market Purchase, stating the purchase price (which shall not be more than the Maximum Price) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase; and

(v) "market day" means a day on which the SGX-ST is open for trading in securities.

(e) any of the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including without limitation, to execute all such documents as may be required and to approve any amendments, alterations or modifications to any documents), as they or he may consider desirable, expedient or necessary to give effect to the transactions contemplated by this Resolution. **(Resolution 11)**
[See Explanatory Note (vi)]

12. Proposed Participation of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, in the Share Option Scheme
THAT approval be and is hereby given for the proposed participation of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, in the Share Option Scheme.

[See Explanatory Note (vii)]

(Resolution 12)

13. Proposed Participation of Dr Lee Yeng Fen, an Associate of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, in the Share Option Scheme
THAT approval be and is hereby given for the proposed participation of Dr Lee Yen Feng, an Associate of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, in the Share Option Scheme.

[See Explanatory Note (viii)]

(Resolution 13)

14. Proposed Grant of Options to Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, under the Share Option Scheme
THAT subject to and contingent upon the passing of ordinary resolution 12 above, approval be and is hereby given for the Proposed Grant of Options to Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, under the Share Option Scheme, pursuant to and in accordance with the Rules of the Share Option Scheme and on the following terms:

- | | |
|---|---|
| (a) Proposed date of grant of Options | Any time within six (6) weeks from the date of the 2019 AGM (i.e., no later than 5 June 2019) |
| (b) Number of Options proposed to be granted and number of Shares comprised in such Options | 158,080 Options comprising 158,080 Shares (representing 0.031% of the issued Shares (excluding Treasury Shares) as at Latest Practicable Date and 0.204% of the total number of Shares available under the Share Option Scheme) |
| (c) Exercise price of Options | Market Price |
| (d) Exercise period of Options | Exercisable at any time after the first anniversary of the date of grant and up to the second anniversary of the date of grant |
| (e) Validity period of Options | Two (2) years from date of grant |

[See Explanatory Note (ix)]

(Resolution 14)

15. Proposed Grant of Options under the Share Option Scheme to Dr Lee Yeng Fen, an Associate of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, under the Share Option Scheme

THAT subject to and contingent upon the passing of ordinary resolution 13 above, approval be and is hereby given for the Proposed Grant of Options to Dr Lee Yeng Fen, an Associate of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, under the Share Option Scheme, pursuant to and in accordance with the Rules of the Share Option Scheme and on the following terms:

- | | |
|---|---|
| (a) Proposed date of grant of Options | Any time within six (6) weeks from the date of the 2019 AGM (i.e., no later than 5 June 2019) |
| (b) Number of Options proposed to be granted and number of Shares comprised in such Options | 23,100 Options comprising 23,100 Shares (representing 0.004% of the issued Shares (excluding Treasury Shares) as at the Latest Practicable Date and 0.030% of the total number of Shares available under the Share Option Scheme) |
| (c) Exercise price of Options | Market Price |
| (d) Exercise period of Options | Exercisable at any time after the first anniversary of the date of grant and up to the second anniversary of the date of grant |
| (e) Validity period of Options | Two (2) years from date of grant |

[See Explanatory Note (x)]

(Resolution 15)

All capitalised terms used in this Notice of Annual General Meeting which are not defined herein shall have the same meaning ascribed to them in the Addendum to the Annual Report 2018.

By Order of the Board

Victor Lai

Company Secretary

Singapore,

9 April 2019

Explanatory Notes:

- Dr Lee Hung Ming, will upon re-election as a Director of the Company, remain as the Executive Vice Chairman.
Mr Lim Wee Hann, will upon re-election as a Director of the Company, remain as an Independent Director, the Chairman of the Remuneration Committee, and a member of the Audit and Nominating Committees, and the Board of Directors (save for Mr Lim Wee Hann) considers him independent for the purposes of Rule 704(7) of the Catalist Rules.
- Ordinary Resolution 6, if passed, will facilitate the payment of Directors' fees during the financial year ending 31 December 2019 in which the fees incurred are payable quarterly in arrears.
- The Ordinary Resolution 8 in item 8 above, if passed, will empower the Directors of the Company, effective until the conclusion of the next annual general meeting of the Company, or the date by which the next annual general meeting of the Company is required by law to be held or such authority is varied or revoked by the Company in a general meeting, whichever is the earlier, to allot and issue Shares, make or grant Instruments convertible into Shares and to issue Shares pursuant to such Instruments, up to a number not exceeding, in total, one hundred per centum (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company, of which up to fifty per centum (50%) may be issued other than on a pro-rata basis to shareholders.

For determining the aggregate number of Shares that may be issued, the percentage of issued Shares (excluding treasury shares and subsidiary holdings) will be calculated based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time Ordinary Resolution 8 is passed after adjusting for new Shares arising from the conversion or exercise of any convertible securities or share options or vesting of share awards which are outstanding or subsisting at the time when Ordinary Resolution 8 is passed and any subsequent bonus issue, consolidation or subdivision of shares.

The Ordinary Resolution 9 in item 9 above, if passed, will empower the Directors of the Company to issue Shares up to an amount in aggregate not exceeding fifteen per centum (15%) of the issued share capital (excluding treasury shares and subsidiary holdings) of the Company pursuant to the Share Option Scheme, and such other share-based incentive scheme or share plan, on the date preceding the date of the relevant grant. This authority is in addition to the general authority to issue Shares sought under Ordinary Resolution 8.

The Ordinary Resolution 10 in item 10 above, if passed, will empower the Directors of the Company, effective until the conclusion of the next annual general meeting of the Company, or the date by which the next annual general meeting of the Company is required by law to be held or such authority is varied or revoked by the Company in a general meeting, whichever is the earlier, to grant awards under the Performance Share Plan in accordance with the provisions of the Performance Share Plan and to allot and issue from time to time such number of fully-paid Shares as may be required to be issued pursuant to the vesting of the awards under the Performance Share Plan subject to the maximum number of Shares prescribed under the terms and conditions of the Performance Share Plan.

The aggregate number of Shares which may be allotted and issued pursuant to the Performance Share Plan and under any other share incentive scheme or share plan adopted by the Company for the time being in force, is limited to fifteen per centum (15%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) of the Company on the day preceding the date of grant of the option and/or award. This authority is in addition to the general authority to issue Shares sought under Ordinary Resolution 8.

The Ordinary Resolution 11 in item 11 above, if passed, will empower the Directors of the Company, effective period commencing from the date on which the ordinary resolution in relation to the proposed renewal of the Share Buyback Mandate is passed in a general meeting and expiring on the earliest of the date on which the next Annual General Meeting is held or is required by law to be held, the date the said mandate is revoked or varied by the Company in a general meeting, or the date on which the purchases of shares pursuant to the Share Buyback Mandate are carried out to the full extent mandated, to repurchase ordinary shares of the Company by way of market purchases or off-market purchases of up to ten per cent (10%) of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the Maximum Price as defined in this Notice of Annual General Meeting.

The rationale for, the authority and limitation on, the sources of funds to be used for the purchase or acquisition including the amount of financing and the financial effects of the purchase or acquisition of ordinary shares by the Company pursuant to the Share Buyback Mandate on the audited consolidated financial statements of the Group for the financial year ended 31 December 2018 are set out in greater detail in the Addendum to the Annual Report.

The Ordinary Resolution 12 in item 12 above, if passed, will approve the participation of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, in the Share Option Scheme. Please refer to the Addendum for more details.

The Ordinary Resolution 13, in item 13 above, if passed, will approve the participation of Dr Lee Yeng Fen, an Associate of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, in the Share Option Scheme. Please refer to the Addendum for more details.

The Ordinary Resolution 14 in item 14 above, if passed, will approve the Proposed Grant of Options to Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, under the Share Option Scheme. Please refer to the Addendum for more details.

The Ordinary Resolution 15 in item 15 above, if passed, will approve the Proposed Grant of Options to Dr Lee Yeng Fen, an Associate of Dr Lee Hung Ming, the Executive Vice Chairman and a Controlling Shareholder of the Company, under the Share Option Scheme. Please refer to the Addendum for more details.

Notes:

- A member who is not a relevant intermediary, is entitled to appoint one or two proxies to attend and vote at the annual general meeting ("Meeting") of the Company.
 - A member who is a relevant intermediary is entitled to appoint more than two proxies to attend and vote at the annual general meeting of the Company, but each proxy must be appointed to exercise the rights attached to a different Share or Shares held by such member."Relevant intermediary" has the meaning ascribed to it in Section 181 of the Companies Act.
- A proxy need not be a member of the Company.
- The instrument appointing a proxy or proxies must be deposited at the Company's Share Registrar and Share Transfer office at 50 Raffles Place, #32-01 Singapore Land Tower, Singapore 048623 not less than forty-eight (48) hours before the time appointed for holding the AGM of the Company.

Personal data privacy:

By submitting an instrument appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the Meeting and/or any adjournment thereof, a member of the Company:

- consents to the collection, use and disclosure of the member's personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of proxies and representatives appointed for the Meeting (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the Meeting (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "Purposes");
- warrants that where the member discloses the personal data of the member's proxy(ies) and/or representative(s) to the Company (or its agents), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the Purposes; and
- agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member's breach of warranty.